cancer research

A new study explains how the loss of genetic material on the Y chromosome may drive cancer development in men. Researchers say age-related loss of parts of the Y chromosome can impair tumour suppression, potentially explaining why certain cancers affect men more severely. The findings could point to new biomarkers and treatment approaches.

New reporting highlights that people who survived cancer in childhood face a significantly elevated risk of serious mental health difficulties in adulthood, including depression, anxiety and other psychiatric conditions. The findings point to long-term psychological effects of early cancer diagnosis and treatment, and renew calls for survivors to receive sustained mental health monitoring and support, not just physical follow-up care, well into their adult lives.

Researchers led by Dr. Jona Kayser at MPZPM report that physical processes in dense cell populations play a decisive role in determining the optimal timing of treatment cycles. The finding addresses treatment resistance, described as one of the key challenges in cancer and antibiotic therapy, and suggests treatment scheduling could be improved by accounting for how densely packed cells interact physically rather than relying on biological factors alone.

New research has identified 485 chemicals used in US pesticide products that are linked to breast cancer. The findings, reported by The Guardian, are raising concerns about consumer and worker exposure to common agricultural chemicals and prompting calls for tighter regulation and further safety review of pesticide ingredients.

UF Health researchers report that cancer diagnoses in the United States drop sharply during holiday periods, while outcomes for patients diagnosed around those dates are worse. The findings suggest holiday disruptions delay screenings and follow-up care, allowing cancers to be caught at later, harder-to-treat stages, and raise questions about how seasonal healthcare patterns affect patient survival.

Researchers report that a 'proliferative pause' — a dormant phase some cancer cells enter before spreading to the brain — may offer a critical window to intervene and stop brain metastasis before it begins. The finding could shape new strategies for preventing one of the deadliest complications of cancer, and is drawing attention from oncology and precision medicine communities.

Researchers publishing in Communications Biology report that deletions and regulatory disruption of the Y chromosome recur across cancers, suggesting loss of this chromosome may play a functional role in tumour development rather than being a harmless byproduct. The findings add to growing interest in how sex chromosome instability shapes cancer risk and progression in men.

Researchers report that biological characteristics of prostate cancer tumours can help identify which patients are most likely to benefit from hormone therapy. The finding suggests tumour biology could be used to tailor treatment decisions rather than applying hormone therapy uniformly. Details of the study, including sample size and clinical impact, were not provided, but the work points toward more personalised prostate cancer care.

Mount Sinai has announced a collaborative research agreement to evaluate a novel liquid radioembolic agent for treating brain tumors. The therapy would deliver radiation directly to tumor tissue in liquid form, an approach being explored for cancers that are difficult to treat surgically. Details on the partner institution, trial design and timeline have not yet been released, and clinical results remain pending.

A Nature study reports that the p53 protein, best known as a tumour suppressor, prevents chromothripsis — the shattering of chromosomes — by keeping transcription and DNA replication in balance. When p53 is missing or inactive, these processes collide, causing catastrophic genome damage that can drive cancer development. The finding links a classic cancer gene to a new mechanism of genome protection, and researchers say it may refine how tumour evolution and genome instability are understood.

Volunteers and advocates with the American Cancer Society's Cancer Action Network visited Capitol Hill to meet with members of Congress, urging support for cancer research funding and patient-focused legislation. The advocacy day brings grassroots concerns about prevention, treatment access, and federal research investment directly to lawmakers, and is part of the organization's ongoing effort to keep cancer policy on the national legislative agenda.